Mote Therapeutics, Inc.
June 22, 2026
Theater 3
Type: Company Presentation
Focus Area:
Immunology
Mote Therapeutics is a next-generation RNA therapeutics company focused on overcoming one of the key limitations in nucleic acid medicine: targeted delivery beyond the liver. The company’s proprietary mobilize™ platform is a modular, scalable, and chemistry-free system that enables functionalization of LNPs with cell-specific targeting capabilities, allowing efficient RNA delivery to previously inaccessible cell types and tissues.
Leveraging its targeted LNP delivery platform, MOTE is advancing a pipeline of in vivo genetic medicines approaching clinical stage development. Its lead program is a CD19/BCMA dual-targeting in vivo CAR-T therapy designed to achieve safe, convenient, and deep depletion of disease-causing B cells for autoimmune indications. The company is also developing additional targeted delivery programs focused on hematopoietic stem cells (HSCs) and other difficult-to-reach cell and organ systems.
Company HQ City:
Lexington
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
Fapon Group
CEO
Vincent Huo
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
Nov 2026
What is your next catalyst (value inflection) update?
First-in-human Investigator-initiated-trial (IIT)
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}